Genovate Biotechnology Co., Ltd. (TPEX:4130)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
31.75
+0.50 (1.60%)
At close: Feb 26, 2026
34.38%
Market Cap 3.61B
Revenue (ttm) 492.41M
Net Income (ttm) 11.68M
Shares Out 113.75M
EPS (ttm) 0.10
PE Ratio 309.16
Forward PE n/a
Dividend 0.10 (0.31%)
Ex-Dividend Date Aug 20, 2025
Volume 669,742
Average Volume 1,490,812
Open 31.65
Previous Close 31.25
Day's Range 31.20 - 32.50
52-Week Range 17.65 - 40.15
Beta 0.31
RSI 52.47
Earnings Date Mar 27, 2026

About Genovate Biotechnology

Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medicine, as well as cosmetics. Genovate Biotechnology Co., Ltd. was founded in 1982 and is based in Hsinchu City, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1982
Employees 194
Stock Exchange Taipei Exchange
Ticker Symbol 4130
Full Company Profile

Financial Performance

In 2025, Genovate Biotechnology's revenue was 492.41 million, a decrease of -3.61% compared to the previous year's 510.86 million. Earnings were 11.68 million, a decrease of -54.54%.

Financial Statements

News

There is no news available yet.